Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme (1 selected)

Guidance programme

Showing 291 to 300 of 305

Guidance, NICE advice and quality standards in development
TitleTypeExpected publication date
Vamorolone for treating Duchenne muscular dystrophy [ID4024]Technology appraisal guidanceTBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]Technology appraisal guidanceTBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]Technology appraisal guidanceTBC
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565Technology appraisal guidanceTBC
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]Technology appraisal guidanceTBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]Technology appraisal guidanceTBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]Technology appraisal guidanceTBC
Vibegron for treating symptoms of overactive bladder ID6300Technology appraisal guidanceTBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]Technology appraisal guidanceTBC
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All